title: Human papillomavirus vaccination in female pediatric cancer survivors.
abstract: OBJECTIVE
  Survivors of childhood malignancy may be at increased risk for HPV infection for biological and cognitive/behavioral reasons. HPV vaccination is currently recommended for females 11-12 years old with catch up vaccination up to age 26 years. The objective of this cross-sectional study was to determine the prevalence of HPV vaccination among female pediatric cancer survivors, age 11-18 years, at Texas Children's Hospital. STUDY DESIGN, SETTING, AND PARTICIPANTS: A 42-question survey was distributed to parents/guardians of 172 long-term cancer survivors from August-November of 2010. Data were analyzed using frequencies, t-tests, and chi-square analyses.
  
  
  METHODS
  Prevalence of HPV vaccination (intention and completion).
  
  
  RESULTS
  Sixty-six persons (38%) responded. The median current age of survivors was 14 years. Most were white/non-Hispanic (48%) or white/Hispanic (37%). Seventy-one percent had discussed HPV vaccination with a healthcare provider. The overall rate of HPV vaccination (≥ 1 dose) was 32%, including 5% of those age 11-12 years (n = 1 of 21), 36% of those age 13-17 years (n = 13 of 36), and 78% of those age 18 years (n = 7 of 9). Of those whose children had not been immunized, 36% intended to do so in the future. Factors associated with HPV vaccination included age ≥13 years, report of sexual activity, and report of having discussed HPV vaccination with a healthcare provider.
  
  
  CONCLUSIONS
  The rate of HPV vaccination among female pediatric cancer survivors is not appreciably different than that seen in the general population.
authors: Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA. lindsey.hoffman@childrenscolorado.org
authors: Lindsey
authors: L
authors: Hoffman
authors: M Fatih
authors: MF
authors: Okcu
authors: ZoAnn E
authors: ZE
authors: Dreyer
authors: Hilary
authors: H
authors: Suzawa
authors: Rosalind
authors: R
authors: Bryant
authors: Amy B
authors: AB
authors: Middleman
mesh_terms: D000293:Adolescent; D016009:Chi-Square Distribution; D002648:Child; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D011795:Surveys and Questionnaires; D017741:Survivors; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control*
chemical_list: D053918:Papillomavirus Vaccines